Overview

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Phase:
Phase 3
Details
Lead Sponsor:
Alcon Research
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Tobramycin
Tobramycin, Dexamethasone Drug Combination